Robert Behounek walked into the Albuquerque ER & Hospital in November with chest pain, severe arm swelling, and trouble breathing. He worried it was a heart attack. A receptionist asked for his insurance card, then told him, "We're not that kind of ER." The cash price for the visit: about $1,600, due up front. Behounek, uninsured, walked out. (STAT+)
The facility is one of a network of micro-hospitals run by Nutex Health, a Houston-based company that operates small, emergency-style hospitals. At most of its locations, Nutex has declined to participate in Medicare. That choice puts the front desk outside the reach of the federal anti-dumping law that has governed American emergency rooms for forty years. (STAT+)
The federal law is the Emergency Medical Treatment and Labor Act, known as EMTALA. Enacted in 1986, it obligates hospitals with emergency departments to provide a medical screening exam to anyone who arrives, regardless of ability to pay, and to stabilize patients with emergency conditions before any transfer or discharge. Codified at 42 U.S.C. §1395dd, EMTALA is the legal reason an uninsured patient can present at any hospital ER in the country and expect to be seen. (Cornell LII)
The statute, and its implementing regulation at 42 CFR §489.24, are gated on a single condition: the facility must participate in Medicare. Hospitals without a Medicare provider agreement are not bound by EMTALA's screening and stabilization rules. The American College of Emergency Physicians describes the scope in similar terms. (eCFR, ACEP)
That condition is what Nutex has built a business around. The company says it voluntarily screens every patient for life-threatening conditions before asking for payment, and that its cash-pay model lets it serve patients who would otherwise drive past a crowded hospital ER. (STAT+)
Multiple patients, including Behounek, say no meaningful screening took place. The discrepancy is the story's hinge. EMTALA itself does not apply to a facility that has opted out of Medicare, and there is no analogous federal audit authority waiting in its place. What remains is a corporate promise and a patchwork of state-licensing rules that varies by jurisdiction.
The promise of profit has drawn investor attention. Nutex is publicly traded on Nasdaq under NUTX, with SEC filings available under CIK 0001479681. Its 2025 Form 10-K shows the company continuing to grow revenue and operating capacity. In March the company announced a second stock repurchase program alongside 2025 results, which it describes as a signal of confidence in its model. (SEC EDGAR index, Form 10-K FY2025, Nutex press release)
A research note hosted on Nutex's own investor site frames the model even more enthusiastically. Titled "Acute Care, High Conviction: Micro-Hospitals Filling the Gap," the note initiates coverage at Buy with a $290 price target and characterizes micro-hospitals as "a self-funding growth engine" sitting between urgent care and overcrowded hospital ERs. The piece is investor marketing material rather than independent equity research, and it carries Nutex's letterhead. (Nutex-hosted initiation note PDF)
Independent commentary has been more cautious. An Acquirers Multiple deep-value post calls Nutex "a deep value healthcare services operator" while flagging the unusual mix of growth and cash burn, and a Stocktitan recap of the 10-K notes unresolved arbitration exposure alongside the growth story. (Acquirers Multiple, Stocktitan)
What the public filings and the STAT+ reporting together make visible is a structural choice, not a billing dispute. EMTALA's drafters in 1986 attached the screening obligation to Medicare participation because nearly every American hospital, at that point, accepted Medicare. The carve-out was the exception that proved the rule. Four decades later, a micro-hospital can decline Medicare, keep the ER signage, and ask for cash at the front desk. The mechanism is durable, and it is not unique to Nutex.
What to watch next is whether anyone audits the only safeguard still in place. Federal EMTALA review authority does not extend to a private facility that has opted out of Medicare, and state licensing boards vary widely in how, or whether, they probe front-desk screening. Behounek's account, and the patient accounts STAT+ describes, will land as evidence in whatever forum picks the question up first. The voluntary-screening promise is now the only thing standing between the current practice and outright refusal of care, and there is no obvious referee for whether the promise is being kept.